利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

32 条记录 (耗时 0.041 秒)

    Amyloidin protease and uses thereof
    1.
    发明授权
    Amyloidin protease and uses thereof 失效
    淀粉蛋白蛋白酶及其用途

    公开(公告)号：US5424205A

    公开(公告)日：1995-06-13

    申请号：US59032

    申请日：1993-05-07

    申请人： Harry F. Dovey ,  Peter A. Seubert ,  Sukanto Sinha

    发明人： Harry F. Dovey ,  Peter A. Seubert ,  Sukanto Sinha

    IPC分类号： C07K16/40 ,  C12N9/64 ,  C12N15/57

    CPC分类号： C12N9/6424 ,  C07K16/40 ,  C12N9/6421

    摘要： A proteolytic enzyme isolated from human tissue which exhibits a proteolytic activity to hydrolyze Met-Asp peptide bond in an amyloid-like substrate is disclosed. This enzyme has been designated "amyloidin" because it proteolytically cleaves a Met-Asp bond similar to the one present in the amyloid precursor protein to release a fragment having the mature Asp terminus of the .beta.-amyloid peptide. Antibodies to the amyloidin protease are also provided. Methods to isolate and purify the amyloidin protease are provided, as well as assays to screen for inhibitors of the amyloidin protease. Also disclosed is the gene encoding the protease and methods for expression of the protease by recombinant DNA means.

    摘要翻译： 公开了从人体组织分离的蛋白水解酶，其表现出蛋白水解活性以水解淀粉样蛋白样基质中的Met-Asp肽键。 这种酶被称为“淀粉样蛋白”，因为它蛋白水解切割与淀粉样蛋白前体蛋白质中存在的Met-Asp键类似的Met-Asp键，以释放具有β-淀粉样蛋白肽成熟Asp末端的片段。 还提供了抗淀粉样蛋白酶的抗体。 提供了分离和纯化淀粉酶蛋白酶的方法，以及筛选淀粉蛋白酶蛋白酶抑制剂的测定法。 还公开了编码蛋白酶的基因和通过重组DNA手段表达蛋白酶的方法。

    Amyloidin protease and uses thereof
    2.
    发明授权
    Amyloidin protease and uses thereof 失效
    淀粉蛋白蛋白酶及其用途

    公开(公告)号：US5292652A

    公开(公告)日：1994-03-08

    申请号：US766351

    申请日：1991-09-30

    申请人： Harry F. Dovey ,  Peter A. Seubert ,  Sukanto Sinha

    发明人： Harry F. Dovey ,  Peter A. Seubert ,  Sukanto Sinha

    IPC分类号： C07K16/40 ,  C12N9/64 ,  C12N15/57

    CPC分类号： C12N9/6424 ,  C07K16/40 ,  C12N9/6421

    摘要： A proteolytic enzyme isolated from human tissue which exhibits a proteolytic activity to hydrolyze Met-Asp peptide bond in an amyloid-like substrate is disclosed. This enzyme has been designated "amyloidin" because it proteolytically cleaves a Met-Asp bond similar to the one present in the amyloid precursor protein to release a fragment having the mature Asp terminus of the .beta.-amyloid peptide. Antibodies to the amyloidin protease are also provided. Methods to isolate and purify the amyloidin protease are provided, as well as assays to screen for inhibitors of the amyloidin protease. Also disclosed is the gene encoding the protease and methods for expression of the protease by recombinant DNA means.

    摘要翻译： 公开了从人体组织分离的蛋白水解酶，其表现出蛋白水解活性以水解淀粉样蛋白样基质中的Met-Asp肽键。 这种酶被称为“淀粉样蛋白”，因为它蛋白水解地切割与淀粉样蛋白前体蛋白质中存在的Met-Asp键类似的Met-Asp键，以释放具有（β） - 淀粉样蛋白肽成熟Asp末端的片段。 还提供了抗淀粉样蛋白酶的抗体。 提供了分离和纯化淀粉酶蛋白酶的方法，以及筛选淀粉蛋白酶蛋白酶抑制剂的测定法。 还公开了编码蛋白酶的基因和通过重组DNA手段表达蛋白酶的方法。

    Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau
    7.
    发明授权
    Methods for aiding in the diagnosis of Alzheimer's disease by measuring amyloid-β peptide (x-≧41) and tau 有权
    通过测量淀粉样蛋白来帮助诊断阿尔茨海默病的方法 肽（x-≥41）和tau

    公开(公告)号：US07811769B2

    公开(公告)日：2010-10-12

    申请号：US10879958

    申请日：2004-06-28

    申请人： Peter A. Seubert ,  Carmen Vigo-Pelfrey ,  Dale B. Schenk ,  Robin Barbour

    发明人： Peter A. Seubert ,  Carmen Vigo-Pelfrey ,  Dale B. Schenk ,  Robin Barbour

    IPC分类号： G01N33/53

    CPC分类号： C07K16/18 ,  C07K14/4711 ,  G01N33/6896 ,  G01N2333/4709 ,  G01N2500/00 ,  G01N2800/2821 ,  Y10S436/811

    摘要： This invention provides methods useful in aiding in the diagnosis of Alzheimer's disease. The methods involve measuring the amount of amyloid-β peptide (x−≧41) in the cerebrospinal fluid of a patient. High levels of the peptide generally are inconsistent with a diagnosis of Alzheimer's. Low levels of the peptide are consistent with the disease and, with other tests, can provide a positive diagnosis. Other methods involve measuring the amounts of both Aβ(x−≧41) and tau. Low levels of Aβ(x−≧41) and high levels of tau are a positive indicator of Alzheimer's disease, while high levels of Aβ(x−≧41) and low levels of tau are a negative indication of Alzheimer's disease.

    摘要翻译： 本发明提供了有助于诊断阿尔茨海默病的方法。 该方法涉及测量淀粉样蛋白的量 肽（x-≧41）在患者的脑脊液中。 高水平的肽通常与阿尔茨海默病的诊断不一致。 低水平的肽与疾病一致，并且与其他检测可以提供阳性诊断。 其他方法包括测量A＆Bgr（x-≥41）和tau的量。 低水平的A＆bgr（x-≧41）和高水平的tau是阿尔茨海默病的阳性指标，而高水平的A＆bgr（x-≧41）和低水平的tau是阿尔茨海默氏病的阴性指标。

    Testing compounds for effects on synaptophysin in transgenic mice expressing an Alzheimer's disease FAD DNA sequence
    8.
    发明授权
    Testing compounds for effects on synaptophysin in transgenic mice expressing an Alzheimer's disease FAD DNA sequence 有权
    测试化合物对表达阿尔茨海默病FAD DNA序列的转基因小鼠中突触素的影响

    公开(公告)号：US07186881B2

    公开(公告)日：2007-03-06

    申请号：US10746473

    申请日：2003-12-23

    申请人： Kate Dora Games ,  Dale B. Schenk ,  Lisa C. McConlogue ,  Peter A. Seubert ,  Russell E. Rydel

    发明人： Kate Dora Games ,  Dale B. Schenk ,  Lisa C. McConlogue ,  Peter A. Seubert ,  Russell E. Rydel

    IPC分类号： A01K67/00 ,  A01K67/027 ,  G01N33/00

    CPC分类号： C07K14/4711 ,  A01K67/0275 ,  A01K67/0276 ,  A01K67/0278 ,  A01K2207/15 ,  A01K2217/00 ,  A01K2217/05 ,  A01K2217/075 ,  A01K2227/00 ,  A01K2267/0312 ,  A01K2267/0356 ,  C07K2319/02 ,  C12N15/8509

    摘要： The construction of transgenic animal models of human Alzheimer's disease, and methods of using the models to screen potential Alzhe## disease therapeutics, are described. The models are characterized by pathologies similar to pathologies observed in Alzheimer's disease, based on expression of all three forms of the β-amyloid precursor protein (APP), APP695, APP751, and APP770, as well as various point mutations based on naturally occurring mutations, such as the London and Indiana familial Alzheimer's disease (FAD) mutations at amino acid 717, predicted mutations in the APP gene, and truncated forms of APP that contain the Aβ region. Animal cells can be isolated from the transgenic animals or prepared using the same constructs with standard techniques such as lipofection or electroporation. The transgenic animals, or animal cells, are used to screen for compounds altering the pathological course of Alzheimer's disease as measured by their effect on the amount of APP, β-amyloid peptide, and numerous other Alzheimer's disease markers in the animals, the neuropathology of the animals, as well as by behavioral alterations in the animals.

    摘要翻译： 描述了人类阿尔茨海默氏病的转基因动物模型的构建，以及使用该模型筛选潜在的阿尔茨海默病治疗剂的方法。 基于所有三种形式的β-淀粉样蛋白前体蛋白（APP），APP695，APP751和APP770的表达以及基于天然存在的突变的各种点突变，模型的特征在于类似于在阿尔茨海默病中观察到的病理学的病理学 ，例如氨基酸717处的伦敦和印第安纳家族性阿尔茨海默病（FAD）突变，APP基因中预测的突变和含有Abeta区的APP的截短形式。 可以从转基因动物中分离动物细胞，或者使用具有标准技术如脂质转染或电穿孔的相同构建体来制备动物细胞。 转基因动物或动物细胞用于筛选改变阿尔茨海默氏病病理过程的化合物，如通过其对动物中APP，β-淀粉样蛋白肽和许多其他阿尔茨海默氏病标志物的量的影响所测量的，神经病理学 动物，以及动物的行为改变。